The payout, tied to VYNE’s pending acquisition by Yarrow Bioscience, totals $16.5 million based on current shares outstanding.
VYNE Therapeutics announced a $0.38 per share special dividend contingent on its merger with Yarrow Bioscience, Inc. The dividend, agreed upon December 17, 2025, aggregates to approximately $16.5 million, calculated on 42,989,506 outstanding shares.
The merger was originally disclosed in late 2025, with the dividend structured as a pre-close distribution to shareholders. No prior special dividends have been issued by VYNE in recent years, making this a unique event tied to the transaction.
Shares of VYNE remained stable in pre-market trading following the announcement.